Subsequently it was demonstrated that pyridoclax sensitises various cancer cells (IGROV1, OAW42‐R, SLOV3, A549 and MSTO‐211 H) to Bcl‐xL knock‐down, and chemoresistant ovarian cancer cells to ABT‐737 (IGROV1‐R10 and SKOV3) at 25 μm, suggesting Mcl‐1 selectivity. Here, BCL2L1 is linked to cancer.